Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.
Friday, February 18, 2022 |
8:00 am – 8:10 am Horizon CME App Overview |
8:10 am – 8:15 am Welcome, Introductions, & CE Housekeeping |
8:15 am – 9:15 am (01) Recent Progress in Cancer Drug Development: New Agents and New Strategies to Optimize Care Rowena (Moe) Schwartz, PharmD, BCOP, FHOPA - University of Cincinnati |
9:15 am – 9:35 am Break | Virtual Exhibit Hall - Meet-the-Clinician & Exhibitor Video Announcement |
9:35 am – 10:35 am (02) Strategies for Managing Patients Previously Treated for Multiple Myeloma Pamela B. Dudkiewicz, DNP, APRN - BC, AOCNP - University of Miami Sylvester Comprehensive Cancer Center |
10:35 am – 10:55 am Break | Virtual Exhibit Hall - Meet-the-Clinician |
10:55 am – 11:55 am (03) What Should APPs Know About Imaging Studies Used to Evaluate Tumor Response in Patients with Cancer? James Costello, MD, PhD - Moffitt Cancer Center |
11:55 am – 12:10 pm Break | Virtual Exhibit Hall - Open Break |
12:10 pm – 12:55 pm Non-CME/CE Presentation Sponsored by Regeneron & Sanofi Genzyme: A treatment Option for Advances NSCLC and two types of Advances Skin Cancers |
12:55 pm – 1:55 pm (04) Managing Drug-Related Dermatologic Reactions in Patients with Cancer: A Focus on Immunotherapy and Targeted Therapies Jonathan Leventhal, MD - Yale School of Medicine |
1:55 pm – 2:55 pm (05) How to Employ Molecular Test Results to Select and Modify Treatment Regimens in Patients with mNSCLC Dan Melzer, PharmD, BCOP - Moffitt Cancer Center |
2:55 pm – 4:10 pm (06) Cancer-Related Thrombosis: The Great Debate on the Best Way to Anticoagulate Victoria Nachar, PharmD, BCOP - University of Michigan |
4:10 pm Closing Comments |
Saturday, February 19, 2022 |
7:10 am – 8:00 am Non CME/CE Presentation: Morning Symposium - Sponsored by Pfizer Oncology: Clinical Trial Evidence for a CDK4/6 Inhibitor Combination Therapy Complemented by an Evaluation of Real-World Effectiveness |
8:00 am – 8:10 am Horizon CME App Overview |
8:10 am – 8:15 am Welcome, Introductions, & CE Housekeeping |
8:15 am – 9:15 am (07) What is New with CAR T-cell Therapy? Jennie M. Goble, PA-C - Medicine Mayo Clinic |
9:15 am – 9:35 am Break | Virtual Exhibit Hall - Meet-the-Clinician & Exhibitor Video Announcement |
9:35 am – 10:35 am (08) COVID-19 and Cancer: Where Are We Now? Abigail Martin, MSN, NP-C - Hope Medical Center |
10:35 am – 10:55 am Break | Virtual Exhibit Hall - Meet-the-Clinician |
10:55 am – 11:55 am (09) Strategies to Support Reproductive Decision-Making Before Initiating Cancer Treatment Erin Taylor, MS, PA-C - MD Anderson Cancer Center |
11:55 am – 12:10 pm Break | Virtual Exhibit Hall - Open Break |
12:10 pm – 12:55 pm Non-CE Symposium Presentation Sponsored by Incyte-PEMAZYRE: PEMAZYRE (pemigatinib): The First FDA-Approved Treatment for Previously Treated, Unresectable Locally Advanced or metastatic Cholangiocarcinoma (CCA) with an FGFR2 Fusion or Rearrangement Jacqueline Weatherly, PA-C - MD Anderson Cancer Center |
12:55 pm – 1:55 pm (10) Head and Neck Cancers: An Overview of Treatment and Management Kedar Kirtane, MD - Moffitt Cancer Center |
1:55 pm – 2:55 pm (11) The Evolving Role of Genomic Sequence Tests in Cancer Therapeutics J. Kevin Hicks, PharmD, PhD - Moffitt Cancer Center |
2:55 pm – 3:55 pm (12) An Update of Interventional Radiologic Techniques Used in Hepatic Malignancy Beau Toskich, MD - Mayo Clinic College of Medicine and Science |
3:55 pm Closing Comments |
$80.00